Experimental combo shows promise in tough lung cancer
NCT ID NCT02812667
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This early-phase study tested whether adding an experimental drug called plinabulin to the standard immunotherapy nivolumab is safe and effective for people with advanced non-small cell lung cancer that has spread. The study enrolled 18 adults whose cancer had worsened after prior chemotherapy. Researchers monitored side effects and measured how well the combination controlled tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.